Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6912 · 1 trial · 1 indication
To assess the safety and tolerability of AZD6912 in healthy participants.
| Arm | Type | Description |
|---|---|---|
| AZD6912 Dose 1 | EXPERIMENTAL | Participants will receive AZD6912 Dose 1. |
| AZD6912 Dose 2 | EXPERIMENTAL | Participants will receive AZD6912 Dose 2. |
| AZD6912 Dose 3 | EXPERIMENTAL | Participants will receive AZD6912 Dose 3. |
| AZD6912 Dose 4 | EXPERIMENTAL | Participants will receive AZD6912 Dose 4. |
| AZD6912 Dose 5 | EXPERIMENTAL | Participants will receive AZD6912 Dose 5. |
| AZD6912 Dose 6 | EXPERIMENTAL | Participants will receive AZD6912 Dose 6. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive Placebo. |
| AZD6912 additional Japanese cohort 1 | EXPERIMENTAL | Participants will receive AZD6912. |
| AZD6912 additional Japanese cohort 2 | EXPERIMENTAL | Participants will receive AZD6912. |
| Name | Type | Description |
|---|---|---|
| AZD6912 | DRUG | AZD6912 will be administered as a single sub-cutaneous dose. |
| Placebo | DRUG | Placebo will be administered as a single sub-cutaneous dose. |
Inclusion Criteria: * Females must have a negative pregnancy test. * Contraceptive use by males and females should be consistent with local regulations. * Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg. * For optional Japanese participants only: * Partici...
Top 20 of 28 competitors
AZD6912 is an investigational small molecule being developed for rheumatoid arthritis. It is currently in Phase 1 clinical development, meaning it has not been approved and is still being studied for safety and tolerability. The drug is administered subcutaneously.
AZD6912 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical research on this drug for the treatment of rheumatoid arthritis.
AZD6912 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants.
AZD6912 has one completed clinical trial, identified as NCT06115967. This Phase 1 study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous AZD6912 in healthy participants. The trial enrolled 40 participants and was conducted in Canada and the United Kingdom.
AZD6912 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for rheumatoid arthritis. The drug is being studied in clinical trials to evaluate its safety and tolerability, but it has not yet received approval from regulatory authorities.